{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-087001","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.109010+00:00","generated_at":"2026-05-31T10:48:55.951296+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Cognition Therapeutics Reports Q2 2024 Financial Results and Positive Phase 2 SHINE Trial Data","bullets":["Phase 2 SHINE trial showed ~40% mean improvement in ADAS-Cog 11 vs placebo in mild-to-moderate Alzheimer's.","Cash and equivalents $28.5M as of June 30, 2024; NIA grant funds remaining $57.3M.","Net loss $7.0M for Q2 2024 vs $4.7M for Q2 2023.","Topline results from SHIMMER study in DLB expected by year-end 2024.","Company planning next phase of Alzheimer's development after SHINE results."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-087001","json":"https://secwatch.observer/filing/0001104659-24-087001.json","markdown":"https://secwatch.observer/filing/0001104659-24-087001.md","text":"https://secwatch.observer/filing/0001104659-24-087001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465924087001/0001104659-24-087001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465924087001/tm2421054d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:48:55.951296+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}